Bright Minds Biosciences Past Earnings Performance
Past criteria checks 0/6
Bright Minds Biosciences's earnings have been declining at an average annual rate of -16.9%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-16.9%
Earnings growth rate
1.1%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -58.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth
Oct 16
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely
Aug 19We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully
Mar 07We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely
Nov 04Revenue & Expenses Breakdown
How Bright Minds Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 2 | 2 |
| 31 Mar 24 | 0 | -5 | 2 | 3 |
| 31 Dec 23 | 0 | -7 | 2 | 5 |
| 30 Sep 23 | 0 | -7 | 2 | 5 |
| 30 Jun 23 | 0 | -9 | 2 | 6 |
| 31 Mar 23 | 0 | -10 | 2 | 7 |
| 31 Dec 22 | 0 | -12 | 2 | 10 |
| 30 Sep 22 | 0 | -15 | 3 | 12 |
| 30 Jun 22 | 0 | -15 | 3 | 12 |
| 31 Mar 22 | 0 | -16 | 3 | 13 |
| 31 Dec 21 | 0 | -13 | 3 | 10 |
| 30 Sep 21 | 0 | -9 | 2 | 6 |
| 30 Jun 21 | 0 | -6 | 2 | 4 |
| 31 Mar 21 | 0 | -3 | 1 | 2 |
| 31 Dec 20 | 0 | -1 | 0 | 1 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
Quality Earnings: DRUG is currently unprofitable.
Growing Profit Margin: DRUG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DRUG is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare DRUG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DRUG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: DRUG has a negative Return on Equity (-58.71%), as it is currently unprofitable.